Brinkman Tara M, Li Chenghong, Vannatta Kathryn, Marchak Jordan G, Lai Jin-Shei, Prasad Pinki K, Kimberg Cara, Vuotto Stefanie, Di Chongzhi, Srivastava Deokumar, Robison Leslie L, Armstrong Gregory T, Krull Kevin R
Tara M. Brinkman, Chenghong Li, Cara Kimberg, Stefanie Vuotto, Deokumar Srivastava, Leslie L. Robison, Gregory T. Armstrong, and Kevin R. Krull, St. Jude Children's Research Hospital, Memphis, TN; Kathryn Vannatta, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Jordan G. Marchak, Emory University School of Medicine, Atlanta, GA; Jin-Shei Lai, Northwestern University Feinberg School of Medicine, Chicago, IL; Pinki K. Prasad, Louisiana State University, Baton Rouge, LA; and Chongzhi Di, Fred Hutchinson Cancer Research Center, Seattle, WA.
J Clin Oncol. 2016 Oct 1;34(28):3417-25. doi: 10.1200/JCO.2016.66.4789. Epub 2016 Jul 18.
In the general population, psychological symptoms frequently co-occur; however, profiles of symptom comorbidities have not been examined among adolescent survivors of childhood cancer.
Parents of 3,893 5-year survivors of childhood cancer who were treated between 1970 and 1999 and who were assessed in adolescence (age 12 to 17 years) completed the Behavior Problems Index. Age- and sex-standardized z scores were calculated for symptom domains by using the Childhood Cancer Survivor Study sibling cohort. Latent profile analysis identified profiles of comorbid symptoms, and multivariable multinomial logistic regression modeling examined associations between cancer treatment exposures and physical late effects and identified symptom profiles. Odds ratios (ORs) and 95% CIs for latent class membership were estimated and analyses were stratified by cranial radiation therapy (CRT; CRT or no CRT).
Four symptoms profiles were identified: no significant symptoms (CRT, 63%; no CRT, 70%); elevated anxiety and/or depression, social withdrawal, and attention problems (internalizing; CRT, 31%; no CRT, 16%); elevated headstrong behavior and attention problems (externalizing; CRT, no observed; no CRT, 9%); and elevated internalizing and externalizing symptoms (global symptoms; CRT, 6%; no CRT, 5%). Treatment with ≥ 30 Gy CRT conferred greater risk of internalizing (OR, 1.7; 95% CI, 1.0 to 2.8) and global symptoms (OR, 3.2; 95% CI, 1.2 to 8.4). Among the no CRT group, corticosteroid treatment was associated with externalizing symptoms (OR, 1.9; 95% CI, 1.2 to 2.8) and ≥ 4.3 g/m(2) intravenous methotrexate exposure was associated with global symptoms (OR, 1.5; 95% CI, 0.9 to 2.4). Treatment late effects, including obesity, cancer-related pain, and sensory impairments, were significantly associated with increased risk of comorbid symptoms.
Behavioral, emotional, and social symptoms frequently co-occur in adolescent survivors of childhood cancer and are associated with treatment exposures and physical late effects. Assessment and consideration of symptom profiles are essential for directing appropriate mental health treatment for adolescent survivors.
在普通人群中,心理症状经常同时出现;然而,儿童癌症青少年幸存者中症状共病的情况尚未得到研究。
1970年至1999年间接受治疗且在青少年期(12至17岁)接受评估的3893名5年存活的儿童癌症幸存者的父母完成了行为问题指数调查。使用儿童癌症幸存者研究的同胞队列,计算症状领域的年龄和性别标准化z分数。潜在类别分析确定共病症状的类别,多变量多项逻辑回归模型检验癌症治疗暴露与身体远期效应之间的关联,并确定症状类别。估计潜在类别成员的比值比(OR)和95%可信区间(CI),并按颅脑放射治疗(CRT;接受CRT或未接受CRT)进行分层分析。
确定了四种症状类别:无明显症状(接受CRT,63%;未接受CRT,70%);焦虑和/或抑郁、社交退缩及注意力问题升高(内化;接受CRT,31%;未接受CRT,16%);倔强行为和注意力问题升高(外化;接受CRT,未观察到;未接受CRT,9%);内化和外化症状均升高(全面症状;接受CRT,6%;未接受CRT,5%)。接受≥30 Gy CRT治疗会增加内化症状(OR,1.7;95% CI,1.0至2.8)和全面症状(OR,3.2;95% CI,1.2至8.4)的风险。在未接受CRT组中,皮质类固醇治疗与外化症状相关(OR,1.9;95% CI,1.2至2.8),≥4.3 g/m(2)静脉注射甲氨蝶呤暴露与全面症状相关(OR,1.5;95% CI,0.9至2.4)。包括肥胖、癌症相关疼痛和感觉障碍在内的治疗远期效应与共病症状风险增加显著相关。
儿童癌症青少年幸存者中行为、情绪和社交症状经常同时出现,且与治疗暴露及身体远期效应相关。评估和考虑症状类别对于指导青少年幸存者进行适当的心理健康治疗至关重要。